Technical Analysis for SLRN - Acelyrin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Overbought | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Inside Day | Range Contraction | 3.34% | |
| Crossed Above 20 DMA | Bullish | 2.20% | |
| Crossed Above 50 DMA | Bullish | 2.20% | |
| MACD Bullish Centerline Cross | Bullish | 2.20% | |
| MACD Bullish Signal Line Cross | Bullish | 2.20% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 2.20% | |
| Pocket Pivot | Bullish Swing Setup | 2.20% |
| Alert | Time |
|---|---|
| Up 2% | about 4 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Up 1% | about 5 hours ago |
| Possible Inside Day | about 6 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/08/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.705 |
| 52 Week Low | 3.36 |
| Average Volume | 1,012,212 |
| 200-Day Moving Average | 5.77 |
| 50-Day Moving Average | 4.81 |
| 20-Day Moving Average | 4.98 |
| 10-Day Moving Average | 5.05 |
| Average True Range | 0.40 |
| RSI (14) | 61.54 |
| ADX | 14.01 |
| +DI | 24.15 |
| -DI | 16.89 |
| Chandelier Exit (Long, 3 ATRs) | 4.42 |
| Chandelier Exit (Short, 3 ATRs) | 5.38 |
| Upper Bollinger Bands | 5.59 |
| Lower Bollinger Band | 4.36 |
| Percent B (%b) | 0.98 |
| BandWidth | 24.72 |
| MACD Line | 0.11 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.0688 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.13 | ||||
| Resistance 3 (R3) | 6.08 | 5.84 | 6.03 | ||
| Resistance 2 (R2) | 5.84 | 5.70 | 5.87 | 6.00 | |
| Resistance 1 (R1) | 5.71 | 5.61 | 5.78 | 5.76 | 5.97 |
| Pivot Point | 5.47 | 5.47 | 5.51 | 5.50 | 5.47 |
| Support 1 (S1) | 5.34 | 5.33 | 5.41 | 5.39 | 5.17 |
| Support 2 (S2) | 5.10 | 5.24 | 5.13 | 5.14 | |
| Support 3 (S3) | 4.97 | 5.10 | 5.11 | ||
| Support 4 (S4) | 5.02 |
